Novo Nordisk stock falls on trial results
Investing.com -- Shares of Novo Nordisk (NYSE: NVO) tumbled 6% today, following the announcement of results from its REDEFINE 2 phase 3 trial. Despite meeting its primary endpoint, showing statistically significant weight loss with its CagriSema treatment compared to placebo, the market reacted negatively.
Novo Nordisk's new obesity drug data disappoints again, shares fall
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
MarketBeat on MSN16h
Despite Challenges Novo Nordisk Plans to Crush GLP-1 CompetitorsNovo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...
We encourage shareholders to exercise their rights by submitting proxies or votes by correspondence in advance of the Annual General Meeting. Also, Novo Nordisk offers the possibility of viewing ...
Zacks.com on MSN4d
Novo Nordisk Lowers Wegovy Costs for Cash-Pay Patients, Stock Up 4%Novo Nordisk NVO announced that it is launching a new direct-to-patient online pharmacy called NovoCare, which will offer its ...
Novo Nordisk US. In a press release, Moore noted that the Company is “meeting or exceeding current and projected nationwide demand.” According to the FDA, to avoid disruption to patient ...
As part of its ongoing efforts to ensure patients who need Wegovy, or semaglutide, injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg can ...
Novo Nordisk's NovoCare will now provide uninsured or underinsured patients access to Wegovy for just $499 per month—less ...
5don MSN
The pharmacy, called NovoCare, will allow patients to pay $499 in cash per month for the blockbuster weight loss drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback